burger_pills.jpg
| | | | |

America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

Part II.  What Do We Get for All That Money?  A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic;  Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;

Seven Independent Investigations give FDA a Failing Grade

FDA’s preeminent authority to determine whether a drug or device is approved is its assumed scientific expertise and honest, independent review of safety and performance data from scientifically valid, controlled clinical trials.  However, surveys of FDA scientists and numerous independent investigations by highly credible entities have all confirmed serious deficiencies…

Vicissitudes of Psychiatry’s Diagnostic Manual Revisions

The latest area of controversy focuses on the proposed revision of the definition "behavioral addiction disorder" extending the addiction diagnosis to include drug, alcohol and gambling.  It is estimated that the change would expand the number of people labeled as "addicts" by 20 to 30 million who would be entitled to treatment and disability payments costing taxpayers many hundreds of millions of dollars.

Petition to FDA: Withdraw Aricept 23mg Immediately

Public Citzen petitioned  FDA Commissioner to immediately removal from market Pfizer’s Alzheimer’s drug, Aricept  23 mg dose, because of serious safety hazards and failure to demonstrate efficacy. The petition also urges FDA to add a label warning on Aricept and generic donepezil (5 mg and 10 mg) stating: "Use of 20 mg per day is counter indicated."

FDA Expands Market for Another Toxic Antipsychotic

According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel (1997), Abilify (2002), and Saphris (2009). These drugs’…